The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas

The primary treatment for gliomas typically involves tumor resection followed by adjuvant radiotherapy, with increasing emphasis on chemotherapy and molecularly targeted drugs. This study aimed to review and summarize the literature on the systemic therapy of malignant gliomas. Chemotherapy may be considered in grades 2 and 3 gliomas, especially when mutations in 1p19q-codeletion are detected. The beneficial impact of adding chemotherapy to radiotherapy (PCV: procarbazine, lomustine, vincristine) has also been demonstrated. In grade 4 glioblastoma multiforme (GBM), wild-type isocitrate dehydrogenase (IDH) status showed the best treatment outcomes with temozolomide (TMZ) in patients with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. Prolonging adjuvant TMZ therapy improves treatment outcomes compared to the standard 6-cycle adjuvant therapy. Bevacizumab (BEV) monotherapy can improve progression-free survival and maintain the initial quality of life. Despite advancements in GBM treatment, outcomes remain unsatisfactory, with a median survival of 14-16 months. Further research is still needed regarding the systemic treatment of central nervous system gliomas.

• Publication year

  2024

• Venue

  Cureus

• Publication date

  2024-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7759/cureus.70532PMID 39439623PMCID 11494030
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.

  2023cited by this paper
• A new targeted therapy for low-grade glioma

  2023cited by this paper
• Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies

  2023cited by this paper
• CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.

  2023influential reference
• WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation.

  2022cited by this paper
• Emerging therapies for glioblastoma: current state and future directions

  2022cited by this paper
• Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches

  2022cited by this paper
• CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

  2021cited by this paper
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

  2021influential reference
• Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study

  2021cited by this paper
• First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide

  2020influential reference
• Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.

  2020influential reference
• CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

  2020cited by this paper
• Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424.

  2020cited by this paper
• Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

  2020cited by this paper
• EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

  2020cited by this paper
• A basic review on systemic treatment options in WHO grade II-III gliomas.

  2020cited by this paper
• The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review

  2020influential reference
• Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)

  2019cited by this paper
• Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma

  2019cited by this paper
• Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study

  2019cited by this paper
• Anti-angiogenic therapy for high-grade glioma.

  2018cited by this paper
• Oncolytic viruses as engineering platforms for combination immunotherapy

  2018cited by this paper
• The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis

  2018cited by this paper
• Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

  2018influential reference
• Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

  2017cited by this paper
• The ambiguous role of bevacizumab in progressive glioblastoma — results from the EORTC 26101 phase III trial

  2017cited by this paper
• Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

  2016cited by this paper
• Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

  2016cited by this paper
• Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

  2016cited by this paper
• Immunovirotherapy with measles virus strains in combination with anti–PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment

  2016cited by this paper
• EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma

  2016cited by this paper
• Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

  2015cited by this paper
• Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

  2015cited by this paper
• Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

  2015cited by this paper
• Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

  2015cited by this paper
• Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

  2015cited by this paper
• Drug and gene delivery across the blood-brain barrier with focused ultrasound.

  2015cited by this paper
• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Epidemiologic and Molecular Prognostic Review of Glioblastoma

  2014cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme

  2014cited by this paper
• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

  2014cited by this paper
• Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.

  2014influential reference
• Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

  2014cited by this paper
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

  2013cited by this paper
• Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

  2013cited by this paper
• Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

  2013cited by this paper
• Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

  2012cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors

  2009cited by this paper
• Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G‐protein coupled formylpeptide receptor FPR

  2008cited by this paper
• Glioblastoma.

  2007cited by this paper
• Grading glioma tumors using OWL-DL and NCI Thesaurus

  2007cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Penetration of intra-arterially administered vincristine in experimental brain tumor.

  2004cited by this paper
• Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

  2004cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper

• The Natural Triterpenoid Alisol B Overcomes Temozolomide Resistance in Glioblastoma Through Multi-Target Mechanisms: Coordinated Epigenetic, Metabolic, and Cell-Cycle Reprogramming

  2026cites this paper
• The impacts of the COVID-19 pandemic on IDH-wildtype glioblastoma survival: A Surveillance, Epidemiology, and End Results Analysis.

  2025cites this paper
• NOD1/RIP2 Pathway Promotes Glioma Progression Through Microglial M2 Polarization

  2025cites this paper